GlassScriptPhysician profile
Kevin Michael Man
NPI 1841350832
$3,073.24
in general payments reported to CMS, 2019-2025
20 companies · $436 in 2025
The $436 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $426 · 2021: $18.44 · 2022: $101 · 2023: $553 · 2024: $251 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216 · Education: $24.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.18 |
| Education | $24.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.83 | 2019-2025 | |
| Janssen Biotech, INC. | $505.94 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $390.03 | 2019-2025 | |
| Gilead Sciences, INC. | $308.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.53 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $125.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.90 | 2019 | |
| Braintree Laboratories, INC. | $115.16 | 2019-2021 | |
| Medtronic, INC. | $92.73 | 2024-2025 | Gi Genius |
| Intercept Pharmaceuticals, INC. | $70.99 | 2020-2024 | Ocaliva |
| Lilly USA, LLC | $68.61 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $65.12 | 2020-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $38.48 | 2019 | |
| Amgen INC. | $28.23 | 2022 | |
| Genzyme Corporation | $25.15 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $24.07 | 2023 | Yuflyma |
| Phathom Pharmaceuticals, INC. | $20.92 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $20.74 | 2019 | |
| Alfasigma USA, INC. | $16.45 | 2020 | |
| Allergan, INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Man listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.